ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 84 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2014. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,881,000 | +2.1% | 789,210 | +12.9% | 0.00% | 0.0% |
| Q3 2016 | $9,678,000 | +48.9% | 698,775 | +6.2% | 0.00% | +100.0% |
| Q2 2016 | $6,500,000 | -36.6% | 657,919 | +8.5% | 0.00% | -50.0% |
| Q1 2016 | $10,253,000 | -21.8% | 606,342 | +3.0% | 0.00% | -33.3% |
| Q4 2015 | $13,109,000 | +77.3% | 588,889 | +87.9% | 0.00% | +50.0% |
| Q3 2015 | $7,394,000 | -71.2% | 313,457 | -0.1% | 0.00% | -66.7% |
| Q2 2015 | $25,662,000 | +48.4% | 313,865 | +68.1% | 0.01% | +50.0% |
| Q1 2015 | $17,288,000 | +144.8% | 186,692 | +6.9% | 0.00% | +100.0% |
| Q4 2014 | $7,063,000 | -5.6% | 174,651 | -42.9% | 0.00% | 0.0% |
| Q3 2014 | $7,483,000 | +55.1% | 305,927 | +0.4% | 0.00% | +100.0% |
| Q2 2014 | $4,825,000 | -1.0% | 304,627 | -5.5% | 0.00% | 0.0% |
| Q1 2014 | $4,874,000 | +18.7% | 322,343 | +7.9% | 0.00% | 0.0% |
| Q4 2013 | $4,106,000 | +70.4% | 298,837 | +133.8% | 0.00% | 0.0% |
| Q3 2013 | $2,410,000 | – | 127,801 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |